Orexin Receptor Antagonism and Sleep in Stimulant Use Disorder

Part of paid clinical trials in Houston, Texas.

Sponsor
The University of Texas Health Science Center, Houston
Study ID
NCT06444256
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Stimulant Use Disorder

Eligibility Criteria

Sex
ALL
Age
18 Years - 65 Years
Healthy Volunteers
Not accepted

Interventions

  • SUVO — DRUG
    Participants will receive 20mg of SUVO for 7 days in the evening before bed on Day 5 through Day 11
  • TAU — DRUG
    Participants will receive supportive care and symptomatic medication per protocol at the inpatient facility.

Study Details

The purpose of this study is to determine the effects of suvorexant (SUVO), on sleep, stress, and drug craving during early abstinence from stimulants and to determine the effects of treatment (SUVO vs. treatment as usual (TAU)) on post-treatment (Days 13-30) residential program length of stay (LOS) and completion rate.

Key Dates

Start date
Jul 25, 2024
Status verified
Sep 2025
Primary completion
Jan 30, 2027
Completion
Jan 30, 2027

Study Design

Enrollment
20 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: SUVO
  • Active Comparator: TAU

Primary Outcome Measure

Change in total sleep duration as assessed by the actigraphy watch [ Time Frame: Baseline (Day 4), Day 5, day 6, day 7, day 8, day 9, day 10, day 11 ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
The University of Texas Health Science Center at HoustonHoustonTexas77030
Heather Webber, PhD
[email protected]
713-486-2723
Jessica Vincent
[email protected]
713-486-2645

Find similar trials in Houston, TX

By research site
The University of Texas Health Science Center at Houston· Houston, TX

Related Studies